Show simple item record

dc.contributor.authorBellmunt, J
dc.contributor.authorKheoh, T
dc.contributor.authorYu, MK
dc.contributor.authorSmith, MR
dc.contributor.authorSmall, EJ
dc.contributor.authorMulders, PFA
dc.contributor.authorFizazi, K
dc.contributor.authorRathkopf, DE
dc.contributor.authorSaad, F
dc.contributor.authorScher, HI
dc.contributor.authorTaplin, M-E
dc.contributor.authorDavis, ID
dc.contributor.authorSchrijvers, D
dc.contributor.authorProtheroe, A
dc.contributor.authorMolina, A
dc.contributor.authorDe Porre, P
dc.contributor.authorGriffin, TW
dc.contributor.authorde Bono, JS
dc.contributor.authorRyan, CJ
dc.contributor.authorOudard, S
dc.date.accessioned2017-03-01T17:52:38Z
dc.date.issued2016-05
dc.identifier.citationEuropean urology, 2016, 69 (5), pp. 924 - 932
dc.identifier.issn0302-2838
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/463
dc.identifier.eissn1873-7560
dc.identifier.doi10.1016/j.eururo.2015.10.021
dc.description.abstractThe duration of prior hormonal treatment can predict responses to subsequent therapy in patients with metastatic castration-resistant prostate cancer (mCRPC).To determine if prior endocrine therapy duration is an indicator of abiraterone acetate (AA) sensitivity.Post-hoc exploratory analysis of randomised phase 3 studies examining post-docetaxel (COU-AA-301) or chemotherapy-naïve mCRPC (COU-AA-302) patients receiving AA. The treatment effect on overall survival (OS), radiographic progression-free survival (rPFS), and prostate-specific antigen (PSA) response analysed by quartile duration of prior gonadotropin-releasing hormone agonists (GnRHa) or androgen receptor (AR) antagonist.Patients were randomised to AA (1000mg, orally once daily) plus prednisone (5mg, orally twice daily) or placebo plus prednisone. Prior endocrine therapy was GnRHa (COU-AA-301, n=1127 [94%]; COU-AA-302, n=1057 [97%], 45.1 mo or 36.7 mo median duration, respectively) and/or orchiectomy (COU-AA-301, n=78 [7%] COU-AA-302, n=44 [4%]); castrated patients received prior AR antagonists (COU-AA-301, n=1015 [85%]; COU-AA-302, n=1078 [99%], 15.7 mo or 16.1 mo median duration, respectively).Cox model was used to obtain hazard ratio and associated 95% confidence interval with statistical inference by log rank statistic.Clinical benefit with AA was observed for OS, rPFS, and PSA response for nearly all quartiles with GnRHa or AR antagonists in both COU-AA-301 and COU-AA-302. In COU-AA-301, patients with a longer duration of prior endocrine therapy tended to have greater AA OS, rPFS, and PSA response benefit, with lead-time chemotherapy bias potentially impacting COU-AA-301 results. Time to castration resistance was not captured. This analysis is limited as a post-hoc exploratory analysis.In the COU-AA-301 and COU-AA-302 studies, AA produced clinical benefits regardless of prior endocrine therapy duration in patients with mCRPC.Metastatic castration-resistant prostate cancer patients derived clinical benefits with abiraterone acetate regardless of prior endocrine therapy duration.
dc.formatPrint-Electronic
dc.format.extent924 - 932
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://www.rioxx.net/licenses/all-rights-reserved
dc.subjectHumans
dc.subjectNeoplasm Metastasis
dc.subjectTaxoids
dc.subjectPrednisone
dc.subjectProstate-Specific Antigen
dc.subjectAntineoplastic Agents, Hormonal
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectDisease-Free Survival
dc.subjectRetreatment
dc.subjectOrchiectomy
dc.subjectSurvival Rate
dc.subjectDouble-Blind Method
dc.subjectMale
dc.subjectGonadotropin-Releasing Hormone
dc.subjectAndrogen Receptor Antagonists
dc.subjectProstatic Neoplasms, Castration-Resistant
dc.subjectAbiraterone Acetate
dc.titlePrior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.
dc.typeJournal Article
dcterms.dateAccepted2015-10-06
rioxxterms.versionofrecord10.1016/j.eururo.2015.10.021
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2016-05
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfEuropean urology
pubs.issue5
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.publication-statusPublished
pubs.volume69
pubs.embargo.termsNot known
icr.researchteamProstate Cancer Targeted Therapy Groupen_US
dc.contributor.icrauthorDe Bono, Johannen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record